MED1 and prostate cancer: The AR is a primary oncogenic driver in prostate cancer (PCa) and is characterized by extensive disordered regions.596 In androgen-dependent PCa cells, AR is co-recruited with MED1 condensates to SE regions, thereby promoting oncogenic transcriptional programs.597 Treatment with EPI-001 in PCa cells has been shown to reduce the formation of AR droplets, indicating its potential utility in therapies aimed at disrupting the AR-MED1 interaction in AR-driven cancers.598